Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4127 - Primary pleomorphic sarcoma (PS) and leiomyosarcoma (LMS) of bone: retrospective analysis of an original series


11 Sep 2017


Poster display session


Bone Sarcomas


Giacomo Giulio Baldi


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


G.G. Baldi1, A. Franchi2, G. Soccianti3, D.A. Campanacci3, D. Greto4, L. Livi5, G. Roselli6, F. Galardi7, S. Bazzurri1

Author affiliations

  • 1 Medical Oncology Unit, Nuovo Ospedale di Prato, 59100 - Prato/IT
  • 2 Pathology Department, University of Florence, Florence/IT
  • 3 Orthopedics Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence/IT
  • 4 Radiotherapy Department, University of Florence, Florence/IT
  • 5 Radiotherapy, Azienda Ospedaliera Universitaria Careggi, Florence/IT
  • 6 Radiology Department, Azienda Ospedaliero-Universitaria Careggi, Florence/IT
  • 7 "sandro Pitigliani" Translational Research Unit, Nuovo Ospedale di Prato, 59100 - Prato/IT


Abstract 4127


To describe the clinico-pathological features of 23 patients affected by primary PS and LMS of bone, to confirm the diagnosis by molecular analysis, to evaluate the clinical outcome and to explore the prognostic impact of these features on disease-free (DFS) and overall survival (OS).


Primary PS and LMS of bone surgically treated from 2004 to 2015 were retrospectively reviewed. We analysed: age, sex, stage, histotype, histological-grade and surgical and/or medical therapy. IDH1 mutational status was evaluated and immunohistochemical staining was performed for smooth muscle actin and desmin. For molecular analysis tumor DNA was extracted from freshly cut FFPE sections by GeneRead™ DNA FFPE (Quiagen) and ddPCR (Bio-rad) was used to determine the presence of IDH1H and IDH1C mutations. DFS and OS rates were calculated according to the Kaplan-Meier method. The differentiation (myogenic, MD, versus non-myogenic, NMD) was correlated with the outcome using Kaplan-Meier method.


23 patients with primary PS or LMS of bone were included in the study. Median age was 49 years (range 13-90), male/female 14/9, 18 had localised disease and 5 metastatic disease, 17 received surgery, 14 received adjuvant therapy, 1 received neoadjuvant chemotherapy and 5 received up-front chemotherapy for advanced disease. All cases were histologically and radiologically reviewed: 17 PS and 6 LMS were identified. All cases were high-grade (FNCLCC grading system). Mutational analysis is currently underway and it will be presented at the meeting. 5-year OS of the whole series was 60% (95% CI; 3,1 – NE) and 5-year DFS was 50% (95% CI; 1,6 – 12,2). Patients with advanced disease are 13: 5-year OS in this subgroup was 38% (95% CI; 2,5 – NE). We identified MD in 11 cases. There were no significant differences between the MD and NMD groups in terms of DFS (logrank p-value=0,6788) and OS (logrank p-value=0,7389).


These primary malignant bone tumours are very rare with poor prognosis after relapse or when radical surgery is not feasible. MD did not predict a worse outcome than NMD in terms of OS and DFS.

Clinical trial identification

Legal entity responsible for the study

Giacomo Giulio Baldi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.